July 2000

Contents

Conference reports

• 4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain

• Tenofovir (PMPA), defining cross-resistance profiles

• DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing

• Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV

• Hydroxyurea is active in vitro against multidrug-resistant HIV

• ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients

• Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification

• Ritonavir/saquinavir combination: effect of ritonavir dosage

• What is the significance of blips in viral load?

• Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001

• A prospective study of strategic treatment interruptions in patients with chronic HIV-infection

• Added value of hydroxyurea or IL-2 to STIs remains uncertain

• Continued benefits from protease inhibitor based therapy despite virological failure

• Do resistance mutations disappear off therapy?

• Selection of PI mutations during slow decay of VL and resistance after PI failure

• Thymidine analogues mutations (TAMS) and other NA-related resistance mutations

• Nevirapine vs efavirenz: the SENC trial

• A warning on simplification strategies: not suitable for all

Antiretrovirals

• Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily

Paediatric care

• Gastrostomy tube (G-tube) insertion for improvement of adherence to HAART in pediatric patients with HIV

Side effects

• Study of amino acid methionine for treatment of myelopathy

• 3rd report of patient whose NRTI-associated lactic acidosis responded to riboflavin (vitamin B2)

Basic science and immunology

• Accelerated replicative senescence of the peripheral immune system induced by HIV infection

Vaccines and microbicides

• NIH suspends enrolment in Remune study

Drug resistance

• Immune response may persist after emergence of protease inhibitor-resistant HIV

Other news

• Hit HIV-1 hard, but only when necessary

On the web

• Prophylaxis and treatment of malaria in the presence of HIV protease inhibitor therapy

• The 4th International AIDS Malignancy Conference

PDFs

• Volume 1 Number 4 July 2000 PDF